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Selective Persistence of Dermal CD8+ T Cells in Lesional Plaque
Psoriasis after Clobetasol-17 Propionate Treatment
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In psoriasis, T-cell infiltration and epidermal hyperproli-
feration are key phenomena which are closely related. Our
aim was to investigate the dynamics among T-cell subsets
in relation to epidermal proliferation and clinical severity
in psoriasis during treatment with an ultra-potent
corticosteroid. Seven psoriasis patients were treated twice
daily for 14 days with clobetasol-17 propionate ointment.
Punch biopsies were taken at day 0, 3, 7 and 14.
Epidermal proliferation marker Ki-67 and CD4+,
CD8+, CD45RO+, CD2+ T cells were quantified by
immunohistochemical techniques and image analysis. The
clinical score declined significantly (60%; pv0.01) and a
47% reduction of Ki-67+ nuclei was observed after only
3 days (pv0.01). In the epidermis all investigated T-cell
subsets were significantly reduced at day 14 (pv0.05). In
the dermis, treatment resulted in a significant decrease of
CD4+, CD45RO+ and CD2+ T cells, but dermal CD8+ T
cells persisted. In psoriasis, reduction of clinical severity
and epidermal proliferation during the early phase of
topical corticosteroid therapy cannot primarily be the
result of decreased T-cell subsets. Furthermore, selective
persistence of dermal CD8+ T cells was observed,
which might be associated with disease relapse.
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Key phenomena in the psoriatic plaque are accumula-
tion of T-cell subsets and epidermal hyperproliferation
with premature keratinization (1–3). In the past, the
keratinocyte was believed to be an initial factor in the
pathogenesis of psoriasis (4). However, in the last two
decades it has been recognized that infiltration of
the skin, mainly by T cells, precedes the changes
in epidermal proliferation and differentiation (5–7).
Biological treatments specifically targeted at T cells are
effective in psoriasis, which demonstrates that T-cell
involvement is not just an epiphenomenon (8–12).
It has been shown that CD4+ T cells (helper T cells)
outnumber CD8+ cells (cytotoxic T cells) in the dermis,
whereas CD8+ T cells are more abundantly present in
the epidermis of the psoriatic plaque (13, 14). The
majority of T cells are of the memory effector subset
(CD45RO+) and, upon activation, these cells strongly
express upregulated amounts of co-stimulatory molecule
CD2 (15, 16). T-cell subsets, in particular CD8+,
CD45RO+ and CD2+, appear in the early phase of the
evolving psoriatic plaque, well before epidermal pro-
liferation is disturbed (1, 17). However, the dynamics of
changes in T-cell subsets and epidermal proliferation in
response to treatments remain less well understood.
It has been proposed that hyper-responsiveness of
psoriatic keratinocytes in reply to growth-promoting
signals from T cells in inflamed skin could result in a
hyperproliferative state of the epidermis (18, 19). It has
been shown that psoriatic hyperproliferation results
from increased recruitment of cycling epidermal cells
and not from a decreased cell cycle time (20).
Immunohistochemical assessment of cycling epidermal
cells is possible with the mononuclear antibody against
a nuclear epitope in proliferating keratinocytes (Ki-67).
Nuclear staining with this antibody in the suprabasal
layers indicates progression through the cell cycle (21).
Topical corticosteroid treatment is a first-line treat-
ment for plaque psoriasis. Corticosteroids are believed
to act through interference with gene transcription by
binding the glucocorticoid receptor and certain DNA
response elements, which account for the anti-
inflammatory, immunosuppressive and anti-mitotic
properties of these drugs in a broad sense: in general
when given systemically and on diseased skin tissue
when applied topically. Actions of glucocorticosteroids
on inflammatory skin disease are numerous: effects on
growth, differentiation and function of lymphocytes,
inhibition of cytokine production, suppression of
fibroblast, Langerhans’ cells and endothelial cell func-
tion, inhibition of leucodiapedesis and an inhibitory
effect on mitotic activity of keratinocytes have all been
reported (22–31).
In order to gain more insight in the role of T cells in
relation to epidermal proliferation in the pathogenesis of
psoriasis, we set out a study to clarify the dynamics of
corticosteroid-induced changes in the psoriatic plaque.
In particular, we asked the question whether changes of
relevant T-cell subsets anticipated or followed reduction
of epidermal hyperproliferation and clinical severity.
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Seven Caucasian patients with mild to moderate chronic
plaque psoriasis participated in the present study. Approval by
the ethics committee was obtained by the national Ethical
Committee and all patients gave informed consent. Inclusion
criteria were: no topical therapy for 2 weeks, no systemic anti-
psoriatic therapy for 4 weeks, and the existence of one or more
active psoriatic plaques with a diameter of at least 3 cm.
Furthermore, patients did not use drugs that could interfere
with the course of psoriasis (e.g. systemic corticosteroids, beta-
blockers, anti-malaria agents or lithium). Patients did not have
relevant co-morbidity and patients with psoriasis inversa were
excluded.
Procedure and clinical outcomes
One solitary plaque of at least 3 cm in diameter was selected as
target lesion. All patients were treated with clobetasol-17
propionate 0.5 mg/g (0.05%) ointment (DermovateH, Glaxo,
UK) for 2 weeks, twice daily, on all lesions except the face,
scalp and intertriginous areas. In each patient, four 4 mm
punch biopsies were taken from representative sites in the
target lesion at 1 cm within the edge of the psoriatic lesion, at
baseline (t50), after 3 days (t53), 1 week (t57) and 2 weeks
(t514) of treatment, respectively. Prior to biopsy, local
anaesthesia was given (xylocaine/adrenaline 1:100,000). Skin
defects were closed with one suture. At each visit the severity
scores (PASI for overall severity and SUM-score for the
severity assessment of the target lesion) were assessed and signs
of irritation were recorded. The SUM-score comprises the
total score for erythema (0–4), scaling (0–4) and induration
(0–4), whereas the Psoriasis Area and Severity Index (PASI)
takes total body area involvement into account as well. PASI
scores range from 0 to 72. Photographs of the target lesions
were taken at baseline and at the end of the study.
Immunohistochemical staining
Biopsies were embedded in Tissue Tek OCT compound (Miles
Scientific, Naperville, USA), instantly frozen in liquid nitrogen
and stored at280 C˚ until use. Staining of the following T-cell
subsets was performed: CD4+, CD8+, CD45RO+ and CD2+.
The Ki-67+ nuclei were stained to assess epidermal prolifera-
tion. Sections were sliced 6 mm thick, air-dried for 30 min and
then fixed in cold acetone for 10 min. Ki-67 sections were fixed
in acetone-ether. After blocking endogenous peroxidase using
0.2% sodium azide for 5 min, they were washed in phosphate-
buffered saline (PBS) for 15 min. Subsequently, the sections
were incubated with the primary antibodies for 1 h.
The following primary antibodies (mouse anti-human)
were used, diluted in 1% bovine serum albumin (Sigma,
St Louis, USA)/PBS: anti-CD2 (1:200) (clone MT910),
anti-CD4 (clone MT310) (1:200), anti-CD8 (clone DK25)
(1:200), anti-CD45RO (clone UCHL1) (1:100) and Ki-67
(clone MIB-1) (1:200), all obtained from DAKO (Copenhagen,
Denmark).
Sections were washed in PBS for 15 min. Secondary IgG-
labelled polymer, HRP anti-mouse EnVision+ (DAKO) was
added for 30 min. The sections were washed again for 15 min
in PBS. To visualize the staining we used AEC + High
Sensitivity Substrate Chromogen for 10 min (DAKO).
Counterstaining was performed with Mayer’s haematoxylin
(Sigma). The sections were washed in tap-water and dried.
Finally, they were mounted in glycerol gelatin (Sigma).
In addition, a section from each patient was stained with
haematoxylin-eosin. After dehydration in alcohol and histo-
safe, these sections were mounted in Permount.
Quantification
Quantification of T-cell subsets was performed at 6200
magnification; CD4, CD8, CD45RO and CD2 positive cells
in the epidermis were counted from the basement membrane
up to the stratum corneum across the whole section (4 mm).
Cells in the dermis were counted from the basement membrane
down to 100 mm under the basement membrane and also
across the whole section. Quantitative cell counts were
expressed as ‘positive cells per mm skin length’.
Image analysis
To analyse Ki-67+ cells, three representative digital photo-
graphs were taken at 6100 magnification. Each photograph
was analysed using IP-lab software. A line, with known length
and following the stratum basale, was drawn after choosing a
representative ‘region of interest’ (ROI). All positive cells
above this line were counted and expressed in the unit ‘positive
cells per mm length of basement membrane’.
Statistical analysis
All analyses were performed using StatisticaH statistical
software, version 6.0. To compare psoriasis severity scores
and the number of positive cells at four different moments in
time we performed one-way analysis of variance (ANOVA). If
significant, Duncan’s post hoc comparison was carried out. A




Six men and one woman participated in this study. One
of these patients had a wound infection at the site of the
first biopsy. The data for this patient were not further
analysed. Of six evaluable patients, the age was 51¡6
(mean¡SEM) years and reported history of psoriasis
was a 31¡7 years.
Clinical response
The PASI at baseline was 10.7¡1.2, declining to
5.0¡1.0 after 2 weeks of therapy. SUM-scores of the
target lesion were 8.8¡0.5 and 3.5¡0.4 at baseline and
after therapy, respectively, reflecting a SUM-score
reduction of 60%. PASI scores had declined significantly
after 7 days (pv0.05), whereas SUM-scores had already
decreased significantly after 3 days (223%; p50.01).
T-cell infiltration
Mean T-cell counts per mm section length are depicted
in Fig 1. The dermis of untreated psoriatic skin showed
counts of CD4+, CD45RO+ and CD2+ T cells of
110¡18, 145¡40 and 127¡41, respectively. In contrast,
the count of CD8+ T cells in untreated dermis of
psoriatic skin was only 27¡9 per mm.
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In the epidermis of untreated psoriatic skin, however,
the CD8+ T-cell count was high (52¡13 per mm),
whereas the CD4+, CD45RO+ and CD2+ T-cell
counts were 20¡4, 19¡5 and 19¡5 per mm section,
respectively.
In the dermis, CD4+, CD45RO+ and CD2+ T cells
showed a substantial reduction, reaching 53%, 67% and
59% of their baseline values after 14 days of treatment.
All these reductions were statistically significant
(pv0.05). In contrast, CD8+ cells in the dermis did
not show any tendency to reduce during treatment, as
illustrated by representative histology in Fig. 2. At 3
and 7 days of treatment none of the dermal T-cell
subsets showed a statistically significant decrease.
In the epidermis, all the T-cell subsets showed a
substantial decrease after 14 days’ treatment, reaching
79% (CD4+), 89% (CD8+), 82% (CD45RO+) and
69% (CD2+), respectively, of the baseline values.
After 7 days’ therapy CD4+, CD8+ and CD45RO+ T
cells had already reached a statistically significant
reduction, but at 3 days’ treatment no T-cell subset
showed a statistically significant change as compared to
baseline.
Epidermal proliferation
The number of Ki-67 positive nuclei per mm basement
membrane was 247¡26 at baseline. After 3, 7 and 14
days the number of Ki-67+ nuclei was 132¡28, 115¡21
and 31¡11, respectively (all values pv0.01 compared to
baseline).
CD8+ T cells and SUM-scores
The dermal T-cell count and individual SUM-scores of
the target lesion did not show a significant correlation
(r50.19). In contrast, the number of epidermal CD8+ T
cells, together with the other T-cell markers, correlated
much better with the SUM-score value (r50.66).
DISCUSSION
The present study describes the time course of T-cell
subset changes in relation to epidermal proliferation
during a 2-week treatment course with clobetasol-17
propionate ointment.
After 2 weeks’ treatment six evaluable patients had a
mean PASI decrease of 54% and mean reduction of the
Fig. 1. T-cell counts (CD4+, CD8+, CD45RO+ and CD2+) per mm section length (mean¡SEM) in dermis (¤) and epidermis (&) during 2 weeks
of topical treatment with clobetasol-17 propionate ointment, twice daily. *Statistically significant difference compared to baseline; NS, not
significant.
Fig. 2. Staining for CD8+ T cells in skin biopsies after 0 (A), 3 (B), 7
(C) and 14 (D) days treatment with clobetasol-17 propionate ointment,
showing selective persistence of CD8+ T cells in the dermis.
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SUM-score of 60%. This was accompanied by an 87%
reduction in Ki-67+ cells in epidermis, 53–67% reduction
of CD4+, CD45RO+ and CD2+ T cells in the dermis
and 69–89% decline in CD4+, CD8+, CD45RO+ and
CD2+ T cells in the epidermis.
These findings confirm and extend the results of
previous studies. For example, De Jong et al. (31) found
a significant PASI reduction and a significant reduction in
epidermal proliferation, measured by Ki-67+ nuclei, after
1 week’s treatment with budesonide ointment. However,
no significant reduction of T cells was observed. In
another study, patients who were treated with betametha-
sone dipropionate showed significant reductions of
SUM-score, epidermal proliferation (Ki-67) and a non-
significant tendency to a decrease of T-cell subsets (32).
Although betamethasone dipropionate and clobetasol-17
propionate are both topical corticosteroids, one is class III
and the other is class IV. In the study by Vissers et al., all
T-cell subsets declined and statistical significance was
almost reached (32). In our opinion, the differences
between the present study and the previous studies are
explained by differences in corticosteroid potency, patient
populations, individual variation in response to cortico-
steroids, and possibly the sites of biopsy.
While significant reductions of the SUM-scores (223%)
and number of Ki-67+ nuclei after 3 days was already
47%, the declines after 3 days in epidermal and dermal
CD4+, CD8+, CD45RO+ and CD2+ T-cell counts were
minor and not statistically significant from baseline.
The highly significant reduction in SUM-score and
epidermal proliferation (Ki-67+ nuclei) in the early
phase of clobetasol-17 propionate treatment thus
cannot be the result of a reduction in T-cell subsets.
Instead, various studies have demonstrated a direct
inhibitory effect of corticosteroids on mitotic activity of
keratinocytes in vitro and in vivo (29, 30). Therefore,
combination therapies with topical corticosteroids and
drugs that exclusively block T-cell activation, such as
alefacept, might be very effective in the treatment of
psoriasis (8–12).
We found CD8+ T cells in the epidermis of untreated
psoriatic plaques to be predominant, whereas other
subsets were mainly found in the dermis. This finding is
a reconfirmation of other studies (1–3, 13, 14). A
remarkable observation, however, was the persistence of
CD8+ T cells in the dermis after 2 weeks of therapy. To
the best of our knowledge this observation has not been
reported earlier. It is attractive to speculate that the
persistence of CD8+ cells in the dermis may be related to
the relatively rapid relapse that may occur after cessation
of treatment with ultra-potent topical corticosteroids.
An earlier study showed a pronounced reduction of
dermal CD8+ T cells and CD45RO+ T cells after
treatment with calcipotriol ointment (32). These differ-
ences between clobetasol-17 propionate and calcipotriol,
with respect to the effect on different T cells, may
explain the superb efficacy of combined treatments of
topical corticosteroids and vitamin D3 derivatives in
psoriasis (33–35).
In the past, experiments with transgenic (SCID) mice
showed that CD4+ T cells (but not CD8+ T cells)
injected into human skin explants induced psoriatic
lesions (36). Recently, it has been postulated that CD4+
T cells may be necessary for providing critical inductive
and helper signals, while CD8+ T cells act as principal
effector cells in the pathogenesis of psoriasis (2). In fact,
it has been shown that depletion of regulatory T cells
(CD4+CD25+) induces a remarkable clonal expansion
of CD8+ cells in the skin (2, 37). It might therefore be
interesting to study the role of regulatory T cells, and
especially their interaction with the CD8+ T cells, during
treatments for plaque psoriasis.
In conclusion, in lesional psoriatic skin, the reduction
of clinical activity and epidermal proliferation in the
early phase of topical corticosteroid therapy cannot
primarily result from a reduction of T cells.
Furthermore, the specific persistence of dermal CD8+
T cells after corticosteroid therapy might account for a
relatively rapid relapse after cessation of ultra-potent
corticosteroid therapy.
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